Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

Heron initiates phase II GUARDS-1 study of Cinvanti for the treatment of COVID-19

July 17, 2020

Recce and Path BioAnalytics collaborate in expanded SARS-CoV-2 program

July 17, 2020

First multitope peptide-based vaccine against SARS-CoV-2 to enter clinical testing

July 17, 2020

Bold Therapeutics reports promising in vitro data on BOLD-100 for COVID-19

July 16, 2020

BioAegis cleared to begin phase II study of rhu-pGSN in severe COVID-19 pneumonia

July 16, 2020

Octapharma reports on use of Octagam IVIG in critically ill patients with COVID-19

July 16, 2020

FDA clears IND for clinical evaluation of long-acting human IL-7 NT-17 for mild COVID-19

July 16, 2020

Zydus begins human dosing with ZyCoV-D vaccine

July 16, 2020

Can-Fite amends phase II COVID-19 study protocol based on FDA guidance

July 16, 2020

Roche patents antibacterials

July 16, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...